$4.71 Billion is the total value of Avidity Partners Management LP's 97 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ATAI | Exit | ATAI LIFE SCIENCES NV | $0 | – | -218,730 | -100.0% | -0.07% | – |
| Exit | SIGHT SCIENCES INC | $0 | – | -145,189 | -100.0% | -0.07% | – | |
| NAUT | Exit | NAUTILUS BIOTECHNOLOGY INC | $0 | – | -600,000 | -100.0% | -0.08% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -35,600 | -100.0% | -0.08% | – |
| LSAQ | Exit | LIFESCI ACQUISITION II CORP | $0 | – | -400,000 | -100.0% | -0.09% | – |
| HCAQ | Exit | HEALTHCOR CATALIO ACQU CORP | $0 | – | -500,000 | -100.0% | -0.11% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -145,100 | -100.0% | -0.13% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -35,000 | -100.0% | -0.13% | – |
| ZETA | Exit | ZETA GLOBAL HOLDINGS CORPcl a | $0 | – | -1,300,000 | -100.0% | -0.17% | – |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCads | $0 | – | -3,836,798 | -100.0% | -0.20% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -1,190,600 | -100.0% | -0.21% | – |
| Exit | ENGAGESMART INC | $0 | – | -275,000 | -100.0% | -0.21% | – | |
| ACIU | Exit | AC IMMUNE SA | $0 | – | -1,739,600 | -100.0% | -0.26% | – |
| GHRS | Exit | GH RESEARCH PLCordinary shares | $0 | – | -560,000 | -100.0% | -0.27% | – |
| LFST | Exit | LIFESTANCE HEALTH GROUP INC | $0 | – | -1,000,000 | -100.0% | -0.32% | – |
| PATH | Exit | UIPATH INCcl a | $0 | – | -319,000 | -100.0% | -0.37% | – |
| SANA | Exit | SANA BIOTECHNOLOGY INC | $0 | – | -774,644 | -100.0% | -0.39% | – |
| IMAB | Exit | I MABsponsored ads | $0 | – | -454,000 | -100.0% | -0.73% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -251,000 | -100.0% | -0.75% | – |
| CMPS | Exit | COMPASS PATHWAYS PLCsponsored ads | $0 | – | -1,162,000 | -100.0% | -0.77% | – |
| EXAS | Exit | EXACT SCIENCES CORP | $0 | – | -369,000 | -100.0% | -0.78% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -152,300 | -100.0% | -2.04% | – |
| XLRN | Exit | ACCELERON PHARMA INCcall | $0 | – | -1,228,100 | -100.0% | -4.68% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -3,021,000 | -100.0% | -8.41% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.